Description
JS212 is an experimental medicine being studied for metastatic colorectal cancer (mCRC). It is a bispecific antibody-drug conjugate (ADC). This means it combines an antibody (designed to target specific proteins on cancer cells) with a chemotherapy drug (the payload). JS212 targets two proteins involved in tumor growth: EGFR and HER3. By targeting both, it aims to enhance its ability to kill cancer cells and potentially overcome resistance to other treatments. It is being tested in combination with standard chemotherapy regimens (like capecitabine, oxaliplatin) and sometimes with other experimental drugs like bevacizumab or JS207. The goal of the clinical trials is to determine the right dose of JS212 and see how well it works and how safe it is in patients with mCRC who have not received prior treatment for advanced disease. The trials are currently recruiting participants.
Mechanism of Action
JS212 is a bispecific antibody-drug conjugate (ADC). The antibody part targets two specific proteins on the surface of colorectal cancer cells, EGFR and HER3. These proteins are involved in signaling pathways that promote tumor growth. The 'drug conjugate' part carries a chemotherapy drug (a topoisomerase I inhibitor) directly to the cancer cells. When JS212 binds to EGFR and HER3, the cancer cell internalizes it, releasing the chemotherapy drug inside, which then kills the cancer cell. This targeted delivery aims to maximize the effect of the chemotherapy while potentially reducing side effects on healthy cells. The specific molecular targets are EGFR and HER3.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.